Anixa Biosciences, Inc. (ANIX) Stock Price
ANIXStock
$3.48+15.61%52W
Market Cap$118.40M
P/E—
PEG Ratio-0.11
Div yield—
Beta0.48
ANIX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)4.07%
Price vs S&P 500 (4W)0.51%
PEG Ratio-0.11
VGM Score41.01
ANIX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q1 2026 | -$0.10 | -$0.07 | +30.00%(+$0.03) | |
| Q4 2025 | -$0.09 | -$0.08 | +11.11%(+$0.01) | |
| Q3 2025 | -$0.09 | -$0.09 | +0.00%(+$0.00) | |
| Q2 2025 | -$0.10 | -$0.07 | +30.00%(+$0.03) |
ANIX Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.10
4.11
4.10
4.10
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ANIXAnixa Biosciences, Inc. | F | — | B | $3.48 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Anixa Biosciences, Inc.
Anixa Biosciences develops cancer vaccines and immunotherapies targeting major oncology indications including breast, ovarian, lung, colon, and prostate cancers. The company operates two primary therapeutic segments: cancer vaccines for treatment and prevention, and CAR-T therapies including lira-cel for ovarian cancer through subsidiary Certainty Therapeutics. Anixa's approach addresses critical unmet needs in oncology through multiple immunotherapy modalities.